Invention Publication
- Patent Title: NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF
-
Application No.: US18573904Application Date: 2022-06-24
-
Publication No.: US20240285778A1Publication Date: 2024-08-29
- Inventor: Pil Ho KIM , Sung Yun CHO , Jae Du HA , Chi Hoon PARK , Jong Yeon HWANG , Hyun Jin KIM , Song Hee LEE , Ye Seul LIM , Han Wool KIM , Sun Mi YOO , Beom Seon SUH , Ji Youn PARK , Je Ho RYU , Jung Min AHN , Hee Jung MOON , Ho Hyun LEE
- Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY , UBIX THERAPEUTICS, INC.
- Applicant Address: KR Daejeon
- Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY,UBIX THERAPEUTICS, INC.
- Current Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY,UBIX THERAPEUTICS, INC.
- Current Assignee Address: KR Daejeon; KR Seoul
- Priority: KR 20210083326 2021.06.25 KR 20220077174 2022.06.23
- International Application: PCT/KR2022/009087 2022.06.24
- Date entered country: 2023-12-22
- Main IPC: A61K47/55
- IPC: A61K47/55 ; A61K47/54 ; A61K47/60
Abstract:
The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
Public/Granted literature
Information query
IPC分类:
